S

Scilex Holding Co
NASDAQ:SCLX

Watchlist Manager
Scilex Holding Co
NASDAQ:SCLX
Watchlist
Price: 13.26 USD 1.3% Market Closed
Market Cap: 100.6m USD

During the last 3 months Scilex Holding Co insiders have not bought any shares, and sold 12.8m USD worth of shares. The stock price has dropped by 21% over this period (open performance analysis).

The last transaction was made on Dec 30, 2025 by Scilex Holding Co , who sold 5.2m USD worth of SCLX shares.

Last Transactions:
Scilex Holding Co
$-5.2m
Scilex Holding Co
Chief Executive Officer
$-4.8m
Scilex Holding Co
Chief Executive Officer
$-2.8m
Shah Jaisim
$+394.2
Ji Henry
$+238.7
Shah Jaisim
$+904.6
Followwill Dorman
$+28.7
Chun Jay
$+135.9
Lemus David
$+51.3
Ji Henry
$+277.7
Wu Yue Alexander
$+542.2
Ma Stephen Hoi
$+185.3
Shah Jaisim
$+849.9
Ji Henry
$+1.3k
Chun Jay
$+1.5k
Shah Jaisim
$+1.5k
Ma Stephen Hoi
$+355.5
Shah Jaisim
$+2k
Sorrento Therapeutics, Inc.
$+2.3k
Sorrento Therapeutics, Inc.
$+576.9
Sorrento Therapeutics, Inc.
$+5k
Sorrento Therapeutics, Inc.
$+4.3k
View All Transactions

During the last 3 months Scilex Holding Co insiders have not bought any shares, and sold 12.8m USD worth of shares. The stock price has dropped by 21% over this period (open performance analysis).

The last transaction was made on Dec 30, 2025 by Scilex Holding Co , who sold 5.2m USD worth of SCLX shares.

Sold
0-3
months
12.8m USD
1
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Scilex Holding Co
Insider Trading Chart

Scilex Holding Co
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Scilex Holding Co
Last Insider Transactions

Global
Insiders Monitor

Scilex Holding Co
Glance View

Market Cap
100.6m USD
Industry
Pharmaceuticals

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.

SCLX Intrinsic Value
Not Available
S

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top